Exelixis
EXEL
$0.57 (2.55%)
1D
1W
3M
1Y
5Y
ALL
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Business Wire • 2 days ago • EXEL
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024InvestorPlace • 16 days ago • EXEL
7 Cheap Biotech Stocks With Major Upside Potential24/7 Wall Street • about 2 months ago • EXEL
Insider Buying Heats Up at Fracker, Aircraft and Boat Makers, and MoreBusiness Wire • about 2 months ago • EXEL
Exelixis to Present at the William Blair 44th Annual Growth Stock ConferenceZacks Investment Research • about 2 months ago • EXEL
Exelixis (EXEL) Settles Cabometyx Patent Litigation With CiplaCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.